Schrödinger Q2 revenue up 29% YoY to $38.5M; net loss widens to $47.7M, maintains 2022 outlook

Schrodinger, Inc.

2022-Q2 EPS reported -$1.15 revenue$87,132,000

Software revenue $30.0M (+25% YoY); drug discovery revenue $8.5M (+48% YoY).
Net loss of $47.7M vs. $35.0M in Q2 2021; gross profit $17.1M (+43%).
Cash, equivalents, and marketable securities ~$513M, down from $529M at March 31, 2022.
IND for MALT1 inhibitor SGR-1505 cleared; Phase 1 trial in B-cell lymphoma expected Q4 2022.
Maintains full-year 2022 guidance: total revenue $161M–$181M, software revenue $126M–$136M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.